Here's Why Cencora (COR) is a Strong Value Stock

Zacks Premium introduces its Style Scores (Value, Growth, Momentum, VGM) as a tool to refine stock selection, complementing the Zacks Rank, which has historically shown a +23.75% average annual return for #1-ranked stocks since 1988. The methodology advises combining top Zacks Ranks (#1 or #2) with A/B Style Scores for optimal performance. Pharmaceutical services provider Cencora (COR) is highlighted as a compelling example, despite its #3 (Hold) Zacks Rank, due to its 'A' VGM and Value Style Score, an attractive 18.32 forward P/E, recent upward revisions by five analysts for its FY2025 earnings to $15.92 per share, and a 6.2% average earnings surprise.

Analysis

Cencora (COR) is presented as a compelling value investment despite its neutral Zacks Rank of #3 (Hold), based on the firm's proprietary Style Score system. The stock's investment thesis is supported by top-tier 'A' ratings for both its overall VGM Score and its specific Value Score. This high value rating is quantitatively justified by an attractive forward P/E ratio of 18.32. The positive outlook is further reinforced by recent analyst activity for fiscal 2025, where five analysts have revised their earnings estimates upward over the last 60 days. This has resulted in a $0.11 increase in the Zacks Consensus Estimate to $15.92 per share. Additionally, Cencora has a demonstrated history of outperforming expectations, boasting an average positive earnings surprise of 6.2%, which signals operational consistency and a potential for continued positive performance.

Key Decisions for Investors

• Value-oriented investors should consider Cencora for their watchlist, as its 'A' Value Score and 18.32 forward P/E ratio suggest it may be trading at a discount.
• Monitor the trend in analyst earnings revisions for fiscal 2025, as the current upward momentum is a key pillar of the bull case presented in the report.
• Weigh the strong value and earnings revision metrics against the neutral #3 (Hold) Zacks Rank, which indicates the stock may lack the strong near-term catalysts of higher-ranked peers within the same analytical framework.